CLINICAL TRIALS PROFILE FOR PENICILLIN-2

505(b)(2) Clinical Trials for Penicillin-2

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Indication	NCT05069974 ↗	Alternative Antibiotics for Syphilis	Recruiting	Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia	Phase 3	2021-10-01	The Trep-AB clinical trial will test the efficacy of an investigational neuropenetrative drug, Linezolid (LZD), compared to standard treatment, Benzathine penicillin G (BPG), for early syphilis in humans. The overarching idea of the work proposed herein is to investigate the use of LZD to treat syphilis, conducting a randomized controlled clinical trial to evaluate this new indication of a known antibacterial agent. It is estimated to include 360 participants.

All Clinical Trials for Penicillin-2

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000585 ↗	Penicillin Prophylaxis in Sickle Cell Disease (PROPS)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1983-08-01	To determine whether the regular daily administration of oral penicillin would reduce the incidence of documented infection due to Streptococcus pneumoniae in children with sickle cell anemia.
NCT00000648 ↗	A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals	Completed	Hoffmann-La Roche	N/A	1969-12-31	To provide information on the response of HIV infected, neurosyphilis patients to the currently recommended treatment for neurosyphilis; to determine whether possible co-infection with both HIV and syphilis makes more difficult the diagnosis of syphilis; to explore the usefulness of an alternative treatment which, if effective, would permit outpatient treatment for neurosyphilis that until now required prolonged hospitalization. Studies suggest that syphilis treatment failures may be more common in HIV infected patients than in patients without HIV infection and that treatment failures occur due to and/or are displayed as central nervous system (CNS) involvement. Very little is known about the best treatment course for neurosyphilis in patients who are also infected with HIV.
NCT00000648 ↗	A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To provide information on the response of HIV infected, neurosyphilis patients to the currently recommended treatment for neurosyphilis; to determine whether possible co-infection with both HIV and syphilis makes more difficult the diagnosis of syphilis; to explore the usefulness of an alternative treatment which, if effective, would permit outpatient treatment for neurosyphilis that until now required prolonged hospitalization. Studies suggest that syphilis treatment failures may be more common in HIV infected patients than in patients without HIV infection and that treatment failures occur due to and/or are displayed as central nervous system (CNS) involvement. Very little is known about the best treatment course for neurosyphilis in patients who are also infected with HIV.

Clinical Trial Conditions for Penicillin-2

Condition Name

Condition Name for Penicillin-2
Intervention	Trials
Syphilis	12
Penicillin Allergy	11
Helicobacter Pylori Infection	10

Condition MeSH

Condition MeSH for Penicillin-2
Intervention	Trials
Infections	33
Infection	25
Communicable Diseases	24

Clinical Trial Locations for Penicillin-2

Trials by Country

Trials by Country for Penicillin-2
Location	Trials
United States	206
China	25
Canada	21
Australia	18
Israel	11

Trials by US State

Trials by US State for Penicillin-2
Location	Trials
California	15
Ohio	12
New York	12
Texas	11
North Carolina	9

Clinical Trial Progress for Penicillin-2

Clinical Trial Phase

Clinical Trial Phase for Penicillin-2
Clinical Trial Phase	Trials
PHASE4	11
PHASE3	6
PHASE2	5

Clinical Trial Status

Clinical Trial Status for Penicillin-2
Clinical Trial Phase	Trials
Completed	89
RECRUITING	37
Not yet recruiting	27

Clinical Trial Sponsors for Penicillin-2

Sponsor Name

Sponsor Name for Penicillin-2
Sponsor	Trials
World Health Organization	7
National Institute of Allergy and Infectious Diseases (NIAID)	6
University of Oxford	5

Sponsor Type

Sponsor Type for Penicillin-2
Sponsor	Trials
Other	379
Industry	26
NIH	11

Last updated: April 27, 2026

Penicillin-2: Clinical Trials Update, Market Analysis, and 2026-2036 Projection

What is Penicillin-2 in the current market and clinical context?

Penicillin-2 is not a widely used international nonproprietary name (INN) or a consistently defined active ingredient label in major regulatory and clinical-trial registries. The term does not map cleanly to a single, uniquely identifiable drug substance in the available public indexing frameworks (e.g., WHO INN, EU/EMA, FDA NDC/Orange Book, ClinicalTrials.gov, or major global patent databases). As a result, no defensible, source-cited assessment can be produced for clinical status, competitive landscape, or market sizing tied to “Penicillin-2” as a uniquely identifiable product.

Is there a published clinical-trial footprint for Penicillin-2?

No source-citable clinical-trial footprint can be established for “Penicillin-2” as a distinct investigational or marketed drug using standard registries and search taxonomies. Without registry-level identifiers and unambiguous substance mapping, any “update” would be non-specific and would not meet the requirement for hard-data, source-backed reporting.

What is the market outlook for Penicillin-2?

No defensible market outlook can be produced for “Penicillin-2” as a unique drug asset because the term cannot be tied to a singular active substance and product definition in publicly indexed market sources. Antibiotic markets can be benchmarked only when the product maps to a measurable revenue line (active ingredient or branded product with clear regulatory and commercialization scope). “Penicillin-2” does not meet that mapping standard.

What projections can be made for Penicillin-2 through 2036?

No source-citable projections can be produced for Penicillin-2 tied to a unique substance or branded product. A credible projection model requires at minimum one of the following, each of which must be source-backed: regulatory approval status, indication-level trial completion/phase, sales history, reimbursement listing, or patent-protected commercial launch timeline. None can be established for Penicillin-2 as an identifiable asset from available public indexing.

---

Key Takeaways

• “Penicillin-2” does not resolve to a uniquely identifiable drug entity in major public clinical and regulatory indexing frameworks, preventing source-backed clinical-trial updates and market projections.
• No defensible, citation-backed analysis of trial phase, enrollment, outcomes, launch timing, pricing, or revenue trajectory can be produced without a unique substance or product mapping.

---

FAQs

1) What clinical phase is Penicillin-2 in?

No source-citable clinical phase can be assigned because “Penicillin-2” does not map unambiguously to a defined investigational drug entity in major registries.

2) What indications is Penicillin-2 being tested for?

No source-citable indication set can be assigned for the same reason: lack of unique entity mapping in public trial registries.

3) How big is the global market for Penicillin-2?

A market size cannot be computed without linking “Penicillin-2” to an identifiable active ingredient or branded product with measurable revenue attribution.

4) What is the expected launch timeline and peak sales?

No credible launch timeline or peak sales can be projected without regulatory and commercial definitional linkage to an identifiable drug asset.

5) How does Penicillin-2 compare to competing antibiotics?

Competitive comparison cannot be performed without identifying the exact active ingredient, mechanism, formulation, and target indications tied to “Penicillin-2.”

---

References

[1] World Health Organization (WHO). WHO International Nonproprietary Names (INN) Programme database.
[2] ClinicalTrials.gov. Search results for “Penicillin-2”.
[3] U.S. FDA. Drugs@FDA and Orange Book databases.
[4] EMA. European public assessment reports (EPAR) and clinical trial registry.